Vital Signals introduced the Signal Ring on Thursday, promising continuous blood pressure monitoring without a cuff or calibration. The $399 device targets users with hypertension through a finger-worn ring paired with an app.
The startup, founded by Tom Moss, tested the ring in a 451-person clinical study. Moss, a former Google executive who experienced a hypertensive crisis, developed the device with engineers from Masimo to provide passive and manual readings throughout the day.
Users can add context such as exercise or meals to readings. The ring offers three days of battery life and ships with a charging case. Preorders opened at $399 with shipments expected in October.
Health experts expressed caution about accuracy. Dr. Lindsey Rosman of the University of North Carolina noted potential issues with motion, skin tone, and irregular heartbeats. The device has not been reviewed by the FDA.
